Our work points the way to potential clinical repurposing of PIs in Onc-p53 NSCLC and possibly other high-frequency Onc-p53 tumors (small cell lung cancer, ovarian cancer, and pancreatic cancer, among others). This evidence concerns the gene TP53 and ovarian carcinoma.